Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients

Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism - a prospective, randomized, controlled study

(2013) Si-Yang Chen et al.   CLINICAL TRANSPLANTATION

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients

(2013) Xiao-cong Zuo et al.   Pharmacogenetics and Genomics

TheCYP3A4*22allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations

(2012) Laure Elens et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients

(2012) H de Jonge et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Simultaneous detection of CYP3A5 and MDR1 polymorphisms based on the SNaPshot assay

(2011) Liang Li et al.   CLINICAL BIOCHEMISTRY

A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients

(2011) L. Elens et al.   CLINICAL CHEMISTRY

Identification of Cytochrome P450 Oxidoreductase Gene Variants That Are Significantly Associated with the Interindividual Variations in Warfarin Maintenance Dose

(2011) X. Zhang et al.   DRUG METABOLISM AND DISPOSITION

Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period

(2011) Xiaoqing Zhang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study

(2011) Liang Li et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients

(2011) Masatomo Miura et al.   PHARMACOGENOMICS

The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients

(2011) Hylke de Jonge et al.   PHARMACOGENOMICS

Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium

(2011) Pamala A. Jacobson et al.   TRANSPLANTATION

A Functional Polymorphism in the CYP3A4 Gene is Associated with Increased Risk of Coronary Heart Disease in the Chinese Han Population

(2010) Bao-xia He et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference

(2009) Pierre Wallemacq et al.   THERAPEUTIC DRUG MONITORING

Genotyping panel for assessing response to cancer chemotherapy

(2008) Zunyan Dai et al.   BMC Medical Genomics

CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients

(2008) Séverine Crettol et al.   THERAPEUTIC DRUG MONITORING